Gain Therapeutics (GANX)
NASDAQ:GANX
Total Valuation
Gain Therapeutics has a market cap or net worth of $78.15M. The enterprise value is $58.04M.
Market Cap$78.15M
Enterprise Value$58.04M
Share Statistics
Gain Therapeutics has 42,241,947 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding42,241,947
Owned by Insiders3.33%
Owned by Institutions4.75%
Financial Efficiency
Gain Therapeutics’s return on equity (ROE) is -1.09 and return on invested capital (ROIC) is -95.04%.
Return on Equity (ROE)-1.09
Return on Assets (ROA)-0.88
Return on Invested Capital (ROIC)-95.04%
Return on Capital Employed (ROCE)-0.96
Revenue Per Employee0.00
Profits Per Employee-876.57K
Employee Count23
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Gain Therapeutics is ―. Gain Therapeutics’s PEG ratio is 0.17.
PE Ratio―
PS Ratio0.00
PB Ratio5.72
Price to Fair Value5.72
Price to FCF-5.75
Price to Operating Cash Flow-3.30
PEG Ratio0.17
Income Statement
In the last 12 months, Gain Therapeutics had revenue of 0.00 and earned -20.16M in profits. Earnings per share was -0.61.
Revenue0.00
Gross Profit-94.05K
Operating Income-18.71M
Pretax Income-19.30M
Net Income-20.16M
EBITDA-18.62M
Earnings Per Share (EPS)-0.61
Cash Flow
In the last 12 months, operating cash flow was -18.47M and capital expenditures -3.00, giving a free cash flow of -18.47M billion.
Operating Cash Flow-18.47M
Free Cash Flow-18.47M
Free Cash Flow per Share-0.44
Dividends & Yields
Gain Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.78
52-Week Price Change12.12%
50-Day Moving Average2.12
200-Day Moving Average2.16
Relative Strength Index (RSI)40.47
Average Volume (3m)840.13K
Important Dates
Gain Therapeutics upcoming earnings date is May 19, 2026, After Close (Confirmed).
Last Earnings DateMar 26, 2026
Next Earnings DateMay 19, 2026
Ex-Dividend Date―
Financial Position
Gain Therapeutics as a current ratio of 6.63, with Debt / Equity ratio of 3.94%
Current Ratio6.63
Quick Ratio6.63
Debt to Market Cap<0.01
Net Debt to EBITDA1.08
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Gain Therapeutics has paid 861.12K in taxes.
Income Tax861.12K
Effective Tax Rate-0.04
Enterprise Valuation
Gain Therapeutics EV to EBITDA ratio is -4.62, with an EV/FCF ratio of -4.66.
EV to Sales0.00
EV to EBITDA-4.62
EV to Free Cash Flow-4.66
EV to Operating Cash Flow-4.66
Balance Sheet
Gain Therapeutics has $20.84M in cash and marketable securities with $732.07K in debt, giving a net cash position of $20.11M billion.
Cash & Marketable Securities$20.84M
Total Debt$732.07K
Net Cash$20.11M
Net Cash Per Share$0.48
Tangible Book Value Per Share$0.56
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Gain Therapeutics is $7.50, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$7.50
Price Target Upside305.41% Upside
Analyst ConsensusStrong Buy
Analyst Count4
Revenue Growth Forecast―
EPS Growth Forecast42.29%